» Download Public Reports
16 reports
- Company report
- May 2011
- 6 pages
May 2011
... Exchange www.Stallergenes.Com innovation is central to stallergenes Identity and promotes the growth of the company, as well as the recognition of allergen immunotherapy treatments which have gained ...
March 2011
... therapy breaks ground for all gene therapy companies. Benitec said that when formally approved, uniqure S glybera, for lipoprotein lipase deficiency, would be The first gene therapy product to be approved ...
March 2011
... As the international family stem cell bank of choice operational review growth in uptake new clients combined storage the relative uptake by new customers of the combined service of storing the umbilical cord ...
February 2012
... Relevant to rheumatoid arthritis, Dr french said. Dr french said that by specifically silencing various genes benitec S dna-directed rna interference (ddrnai) technology was capable of modulating stem cells ...
April 2012
... Sweden) and evry (france) Revenue generated from product sales, r&d collaborations with multinationals as well as grants Currently partner in > 100 m stem cell research programs funded by eu ...
October 2012
... Sis factor a introduction significant impairments of several aspects of immunity, in- cluding phagocytosis, cell-proliferation response to mitogens, t lymphocyte number, and cytokine production have ...
September 2012
... The ministry of health labour and welfare is taking the lead in establishing domestic production and supply of pandemic influenza vaccine using cell- culture technology, Which is expected to shorten ...